Aclaris Therapeutics (ACRS) Insider Trading & Ownership $2.39 +0.03 (+1.27%) Closing price 04:00 PM EasternExtended Trading$2.35 -0.04 (-1.63%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Aclaris Therapeutics (NASDAQ:ACRS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage6.40%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$4.48 MNumber OfInsiders Selling(Last 12 Months)0 Get ACRS Insider Trade Alerts Want to know when executives and insiders are buying or selling Aclaris Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ACRS Insider Buying and Selling by Quarter Aclaris Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/19/2024Anand MehraDirectorBuy666,666$2.25$1,499,998.50 7/30/2024Braden Michael LeonardMajor ShareholderBuy173,730$1.30$225,849.00 7/22/2024Braden Michael LeonardMajor ShareholderBuy17,716$1.33$23,562.28 7/18/2024Braden Michael LeonardMajor ShareholderBuy130,317$1.30$169,412.10 7/5/2024Braden Michael LeonardMajor ShareholderBuy123,017$1.15$141,469.55 7/3/2024Braden Michael LeonardMajor ShareholderBuy143,288$1.16$166,214.08 7/1/2024Braden Michael LeonardMajor ShareholderBuy107,434$1.14$122,474.76 6/27/2024Braden Michael LeonardMajor ShareholderBuy235,000$1.15$270,250.00 6/17/2024Braden Michael LeonardMajor ShareholderBuy150,000$1.13$169,500.00 6/13/2024Braden Michael LeonardMajor ShareholderBuy528,621$1.15$607,914.15 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 6/11/2024Braden Michael LeonardMajor ShareholderBuy1,000,000$1.08$1,080,000.00 (Data available from 1/1/2013 forward) ACRS Insider Trading Activity - Frequently Asked Questions Who is on Aclaris Therapeutics's Insider Roster? The list of insiders at Aclaris Therapeutics includes Anand Mehra, Andrew N Schiff, Braden Michael Leonard, Douglas J Manion, Frank Ruffo, James Loerop, Joseph Monahan, Kevin Balthaser, and Neal Walker. Learn more on insiders at ACRS. What percentage of Aclaris Therapeutics stock is owned by insiders? 6.40% of Aclaris Therapeutics stock is owned by insiders. Learn more on ACRS's insider holdings. Which Aclaris Therapeutics insiders have been buying company stock? The following insiders have purchased ACRS shares in the last 24 months: Anand Mehra ($1,499,998.50), Braden Michael Leonard ($2,976,645.92), Douglas J Manion ($50,310.00), and James Loerop ($99,994.00). How much insider buying is happening at Aclaris Therapeutics? Insiders have purchased a total of 3,296,994 ACRS shares in the last 24 months for a total of $4,626,948.42 bought. Which Aclaris Therapeutics insiders have been selling company stock? The following insiders have sold ACRS shares in the last 24 months: James Loerop ($59,268.63), Joseph Monahan ($319,156.00), Kevin Balthaser ($12,290.00), and Neal Walker ($358,730.00). How much insider selling is happening at Aclaris Therapeutics? Insiders have sold a total of 67,067 Aclaris Therapeutics shares in the last 24 months for a total of $749,444.63 sold. Aclaris Therapeutics Key ExecutivesDr. Neal S. Walker D.O. (Age 54)M.D., Co-Founder, President, Chairman & Interim CEO Compensation: $73.5kMr. Kevin Balthaser (Age 36)Chief Financial Officer Compensation: $581.52kDr. Joseph Monahan Ph.D. (Age 67)Chief Scientific Officer Compensation: $492.43kMr. James Loerop (Age 59)Chief Business Officer Compensation: $570kMr. Matthew Rothman J.D.General Counsel & Corporate SecretaryDr. Jon Jacobsen Ph.D.Senior Vice President of ChemistryMr. Steve TuckerSenior Vice President of Project LeadershipMr. Ajay Aggarwal M.B.A.M.D., Senior Vice President of Clinical Development More Insider Trading Tools from MarketBeat Related Companies Ginkgo Bioworks Insider Buying LENZ Therapeutics Insider Buying Pliant Therapeutics Insider Buying Verve Therapeutics Insider Buying Bicara Therapeutics Insider Buying Dianthus Therapeutics Insider Buying CARGO Therapeutics Insider Buying Tectonic Therapeutic Insider Buying Kura Oncology Insider Buying Immunome Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for Investors This page (NASDAQ:ACRS) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersThe #1 Stock for Trump’s Second Term?Imagine how much money you could make if you bought all of the top performing stocks during Trump's second ter...InvestorPlace | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredDonald Trump is about to free crypto from its chains …On October 25th, Juan said Bitcoin would cross $100,000 before the inauguration. Now he thinks it could rea...Weiss Ratings | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
